Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorArgilés Martinez, Guillem
dc.contributor.authorSobrero, Alberto
dc.contributor.authorBorg, Christophe
dc.contributor.authorOhtsu, Atsushi
dc.contributor.authorMayer, Robert
dc.date.accessioned2021-09-20T13:10:54Z
dc.date.available2021-09-20T13:10:54Z
dc.date.issued2020-08-19
dc.identifier.citationTabernero J, Argiles G, Sobrero AF, Borg C, Ohtsu A, Mayer RJ, et al. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open. 2020 Aug 19;5:e000752.
dc.identifier.issn2059-7029
dc.identifier.urihttp://hdl.handle.net/11351/6334
dc.descriptionChemotherapy; Metastases; Prognosis
dc.description.abstractBackground The choice of treatment in patients with metastatic colorectal cancer (mCRC) is generally influenced by tumour and patient characteristics, treatment efficacy and tolerability, and quality of life. Better patient selection might lead to improved outcomes. Methods This post hoc exploratory analysis examined the effect of prognostic factors on outcomes in the Randomized, Double-blind, Phase 3 Study of trifluridine tipiracil (FTD/TPI) plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with mCRC Refractory to Standard Chemotherapies (RECOURSE) trial. Patients were redivided by prognosis into two subgroups: those with <3 metastatic sites at randomisation (low tumour burden) and ≥18 months from diagnosis of metastatic disease to randomisation (indolent disease) were included in the good prognostic characteristics (GPC) subgroup; the remaining patients were considered to have poor prognostic characteristics (PPC). Results GPC patients (n=386) had improved outcome versus PPC patients (n=414) in both the trifluridine/tipiracil and placebo arms. GPC patients receiving trifluridine/tipiracil (n=261) had an improved median overall survival (9.3 vs 5.3 months; HR (95% CI) 0.46 (0.37 to 0.57), p<0.0001) and progression-free survival (3.3 vs 1.9 months; HR (95% CI) 0.56 (0.46 to 0.67), p<0.0001) than PPC patients receiving trifluridine/tipiracil (n=273). Improvements in survival were irrespective of age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), KRAS mutational status, and site of metastases at randomisation. In the trifluridine/tipiracil arm, time to deterioration of ECOG PS to ≥2 and proportion of patients with PS=0–1 discontinuing treatment were longer for GPC than for PPC patients (7.8 vs 4.2 months and 89.1% vs 78.4%, respectively). Conclusion Low tumour burden and indolent disease were factors of good prognosis in late-line mCRC, with patients experiencing longer progression-free survival and greater overall survival.
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesESMO Open;5
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer
dc.subjectRecte - Càncer
dc.subjectQuimioteràpia combinada
dc.subject.meshColorectal Neoplasms
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.mesh/therapeutic use
dc.titleEffect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1136/esmoopen-2020-000752
dc.subject.decsneoplasias colorrectales
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.1136/esmoopen-2020-000752
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Tabernero J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, Barcelona, Catalunya, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Argiles G] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Catalunya, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Sobrero AF] Medical Oncology Ospedale Policlinico San Martino Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia. [Borg C] Department of Medical Oncology, University Hospital Centre Besançon, Besancon, Bourgogne Franche-Comté, France. [Ohtsu A] Kashiwa, National Cancer Center-Hospital East, Kashiwa, Chiba, Japan. [Mayer RJ] Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
dc.identifier.pmid32817131
dc.identifier.wos000564366600005
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record